Financial Data and Key Metrics Changes - The company reported a net loss of $45.3 million or $1.04 per share for Q2 2025, compared to a net loss of $23.7 million or $0.62 per share for Q2 2024, indicating a significant increase in losses [26] - Non-GAAP adjusted net loss was $40.5 million or $0.93 per share for Q2 2025, compared to a non-GAAP adjusted net loss of $22.2 million or $0.58 per share for Q2 2024 [26] - Research and development expenses increased to $40.2 million for Q2 2025 from $22.5 million in Q2 2024, driven by increased employee and consulting expenses and costs related to ongoing clinical trials [26][27] - General and administrative expenses rose to $3.8 million for Q2 2025 from $1.8 million in Q2 2024, primarily due to increased employee and consulting expenses [27] - The company ended the quarter with approximately $168.4 million in cash, cash equivalents, and short-term investments, which is expected to increase to approximately $455 million after accounting for recent financing activities [28] Business Line Data and Key Metrics Changes - The company achieved significant milestones in its clinical trials, including positive top-line data from the VICTORIA-one trial for patients with HR positive HER2 negative advanced breast cancer, demonstrating unprecedented improvements in progression-free survival (PFS) [6][10] - The median PFS for the gadatholitinib triplet was reported at 9.3 months compared to 2 months for fulvestrant, with a hazard ratio of 0.24, indicating a 4.2 times higher likelihood of survival without disease progression [10][11] - The company also dosed the first patient in the VICTORIA-two trial, which evaluates gadatholitinib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment [8][18] Market Data and Key Metrics Changes - The addressable market potential for a standard of care second-line therapy for the targeted patient population is estimated at approximately $5 billion [18] - There are approximately 34,000 patients moving to second-line treatment after progressing on a CDK4/6 inhibitor, with around 60% being PIK3CA wild type, indicating a large opportunity for the company's therapies [14] Company Strategy and Development Direction - The company aims to establish gadatholitinib as a new standard of care therapy for patients with HR positive HER2 negative advanced breast cancer, focusing on both PIK3CA wild type and mutated populations [6][10] - The company plans to submit a new drug application to the FDA in 2025 based on data from the PIK3CA wild type cohort [13] - The company is preparing for a potential launch of gadatholitinib, having built a commercial team and infrastructure to support the launch [48][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market landscape for gadatholitinib, highlighting the significant unmet need for more efficacious therapies in the second-line treatment space [14][15] - The company believes that the favorable safety profile and efficacy of gadatholitinib will position it well against currently available therapies [12][15] - Management is confident in the robustness of the data and the preparations for the NDA submission, indicating a strong belief in the potential approval and market entry [70] Other Important Information - The company raised approximately $287 million through public offerings of convertible notes, common stock, and pre-funded warrants, providing necessary funding for its operations and clinical trials [10][24] - A new patent was issued extending the exclusivity of gadatholitinib into 2042, allowing the company to optimize its development strategy [23][24] Q&A Session Summary Question: What to expect from the upcoming full data presentation for the PIK3CA wild type portion of the Phase III study? - The company will focus on primary analyses and endpoints, with additional subgroup analyses expected at subsequent meetings [30][31] Question: What benchmarks for success are considered for the PIK3CA mutant population? - A statistically significant result would be clinically meaningful if it shows an improvement of less than three months compared to historical data [32] Question: Can more safety data be provided ahead of the full presentation? - Detailed safety data will be provided at the upcoming conference, with a general summary available at this stage [37] Question: Will PFS analysis based on investigator assessment be presented later this year? - The selection of BICR for the study was to eliminate investigator bias, and the investigator data will be used for exploratory analysis [40][42] Question: How is the company preparing for launch readiness? - The company has been building its team and infrastructure since last year, focusing on key positions to support the launch [48][52] Question: What are the practical ramifications for physicians with both doublet and triplet options? - Having both regimens allows physicians to optimize treatment based on patient needs, providing flexibility in managing disease progression [55][56] Question: Is there a consideration for a commercial partnering strategy for the launch? - The company plans to launch itself, believing it has the necessary infrastructure and capital to do so effectively [58][59] Question: What are the competitive landscape thoughts regarding the mutant population? - The company believes that positive data will position it well against competitors, particularly in the context of PIK3CA mutations [65][66]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was €614.2 million, representing a 4.5% year-over-year growth, with a 1% growth in organic constant currency and 0.5% sequential growth [6][30] - Non-IFRS adjusted operating margin was 15% for the quarter, maintaining stability despite foreign exchange headwinds [30] - Non-IFRS adjusted diluted EPS for the quarter was $1.53, an increase from $1.51 in the previous year [30] - Free cash flow for the quarter was negative $2.9 million, an improvement from negative $28 million in the same period last year [31] Business Line Data and Key Metrics Changes - The AI Pods subscription model has gained traction, with 18 clients adopting this new model, contributing significantly to recent pipeline growth [8][41] - The company is focusing on high-value clients in sectors such as healthcare, financial services, consumer packaged goods (CPG), and gaming [6][30] Market Data and Key Metrics Changes - North America accounted for 54.1% of revenue, Latin America 19.7%, and Europe 19.6%, with Europe being the fastest-growing region at 8.1% sequentially [16] - New markets grew 84% year-over-year, currently representing 6.6% of total revenue, with the Middle East leading this surge [17] Company Strategy and Development Direction - The company is implementing a business optimization plan to align workforce skills with strategic priorities, resulting in a reduction of approximately 1,000 employees or 3% of the workforce [33] - The focus is on building a structurally agile organization to compete effectively in an evolving landscape while delivering strong results for shareholders [6][30] - The company aims to enhance its AI capabilities through partnerships with major AI leaders like OpenAI and AWS, integrating advanced models into its offerings [14][28] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding pipeline conversion, noting that while the macro environment remains uncertain, there are positive signs of recovery in North America and Latin America [48][72] - The company expects revenue for the full year 2025 to be at least $2.445 billion, representing a 1.2% year-over-year growth [35] Other Important Information - The company recorded a one-time charge of $47.6 million in Q2 due to the optimization plan, which is expected to generate $80 million in annualized savings [33] - The AI Pods model is designed to provide guaranteed time and cost savings, shifting the value proposition to concrete results [8][30] Q&A Session Summary Question: Can you provide more details on the AI-based delivery model and subscription side? - The company has 18 paying customers under the subscription model, which has been well received, generating code and software needed by clients [41][42] Question: How far along are the initial changes from the optimization plan? - Additional reductions are expected in Q3, with most of the plan already implemented [50][51] Question: How is the creative performance of the GUT relative to other studios? - The creative pillar has been growing nicely, with no significant impact from AI on high-level strategic work [56][59] Question: Is the enterprise AI platform creating enhanced stickiness with customers? - The enterprise AI platform is becoming essential for clients, integrating complex AI ecosystems and enhancing client engagement [64][66] Question: Can you discuss the revised growth outlook and assumptions? - The revised outlook reflects stabilization in Latin America and a positive trend in the pipeline, with expectations for recovery in the US market [78][80]

Financial Data and Key Metrics Changes - The net loss for the second quarter of 2025 was $25.4 million or $0.43 per share, compared to a net loss of $33.5 million or $0.58 per share in the first quarter of the same year [9][24] - As of June 30, 2025, the company had $28.7 million in cash and investments, bolstered by a registered direct offering that raised $20.6 million in net proceeds [9][10] - Total operating expenses from continuing operations for the second quarter were $32.4 million, a decrease of $2.6 million from the first quarter [26] Business Line Data and Key Metrics Changes - Research and development expenses in the second quarter were primarily focused on Zaltanopart and narsoplimab [27] - Interest expense for the second quarter was near zero, primarily due to an $8.5 million non-cash remeasurement adjustment related to the DRI Amidrea royalty obligation [27] Market Data and Key Metrics Changes - The global market for paroxysmal nocturnal hemoglobinuria (PNH) is projected to grow at 11% annually, reaching over $10 billion by February 2032 [20] - The complement inhibitor segment is expected to more than double from $2.2 billion today to $4.7 billion over the next seven years [20] Company Strategy and Development Direction - The company is focused on the anticipated approval and launch of narsoplimab, targeting the initial indication of stem cell transplant-associated thrombotic microangiopathy (TATMA) [11][12] - The company aims to leverage its experienced field marketing team and skilled sales force to drive rapid uptake of narsoplimab upon approval [18] - Discussions regarding potential asset acquisition and licensing agreements involving clinical assets are ongoing, with one transaction expected to be a multibillion-dollar deal [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the approval process for narsoplimab, with the FDA indicating that labeling discussions are planned to begin no later than October 2025 [13] - The company is optimistic about the market opportunity for narsoplimab, especially given the safety and efficacy data compared to existing treatments [14][15] Other Important Information - The company has adequate supply for narsoplimab for the first several years post-launch, ensuring no supply challenges [53] - The company is advancing its oncology platform, including IND enabling studies for its Oncotox biologics program targeting acute myeloid leukemia (AML) [23] Q&A Session Summary Question: Comparison of narsoplimab launch to Omidria - Management noted that the market for narsoplimab is significantly more focused than that for Omidria, with fewer salespeople needed due to the limited number of transplant centers [37][38] Question: Comfort level of clinicians regarding narsoplimab - Physicians are eagerly awaiting the approval of narsoplimab, viewing it as a much-needed solution for patients facing lethal complications post-transplant [44] Question: Anticipated launch timeline post-approval - If approved in December, the launch would occur in the first quarter of the following year, with substantial supply already in place [50][51] Question: FDA's request leading to PDUFA delay - The FDA requested additional analyses, which were extensive, leading to the three-month delay in the PDUFA date [58][60] Question: Potential partnerships - There is substantial interest in partnerships across the company's programs, but specific details are limited due to confidentiality requirements [61]

Financial Data and Key Metrics Changes - The company recorded its first revenue of just over $90,000 in Q2 2025, marking a significant milestone in its history [22] - The net loss for the quarter was $4,690,000, compared to $1,460,000 for the same quarter in 2024 and $1,980,000 for Q1 2025 [22][23] - Operating expenses increased to $4,630,000 from $1,480,000 in the same quarter last year, largely due to costs associated with the public listing [22][23] - The cash balance at the end of the quarter was $607,000, an increase of $478,000 from the previous balance [23][24] Business Line Data and Key Metrics Changes - The company is focused on three key areas: commercialization and operational excellence, patents and partnerships, and building recurring value [10][12] - The partnership with Hancock Health is a multi-year project aimed at piloting the ArrivePoints in hospitals for secure robotic delivery [25][29] Market Data and Key Metrics Changes - The company is targeting the $191 billion US package delivery market, with a focus on integrating drones into the national airspace [8] - The pilot programs launched with hospitals, retail partners, and municipalities are validating the capabilities of the platform [6][29] Company Strategy and Development Direction - The company aims to transition from pilot projects to defining and dominating key market verticals, focusing on building a defensible mode of intellectual property and strategic partnerships [6][7] - The five-year plan includes scaling production to 10,000 units annually by year four and 100,000 units by year five, with a goal of a tenfold increase in company value [19][26] - The strategy emphasizes a platform as a service model, where revenue grows with every delivery and new ArrivePoint deployed [12][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current market conditions and the company's positioning within the autonomous delivery landscape [14][40] - The recent regulatory changes regarding drone operations are seen as a watershed moment for innovation in the logistics sector [8][29] Other Important Information - The company has filed two additional patent applications and secured a cornerstone patent for its intelligent chain of custody delivery network [32][35] - The management team is focused on building a scalable and defensible business model, with a disciplined approach to capital use [21][25] Q&A Session Summary Question: How does the company plan to transition from its current pilot-centric pre-revenue model to a scalable profitable business? - The COO outlined a strategic five-year plan focusing on product development and partnerships to achieve scalability [46] Question: How will your platform as a service model work? - The COO explained that the model will include a network as a service fee, a marketplace for demand resolution, and AI platform services [48][49] Question: Do you anticipate the new tariffs will materially affect your supply chain costs? - The Chief Strategy Officer mentioned plans to onshore production to the US to mitigate potential tariff impacts [81] Question: What would help Arrive AI succeed in the short term and long term? - The Chief Strategy Officer highlighted the importance of regulatory changes allowing beyond visual line of sight operations for drones [91] Question: What are the biggest risks you see in the next few quarters? - The CFO noted that success will depend on the number of pilots deployed and the learnings from those deployments [96] Question: How is Arrive AI positioned to weather economic downturns? - The CFO emphasized focusing on internal strategies and deployments rather than external market volatility [101] Question: What are your thoughts on potential partnerships with major delivery companies? - The CEO indicated ongoing conversations with various companies but could not disclose specifics due to NDAs [106]

Financial Data and Key Metrics Changes - Operating expenses were reduced by 26% from Q1 to Q2 2025, declining to $3.3 million from $4.5 million [29] - Year-to-date operating expenses are down 14% compared to the same period last year, from $9.1 million to $7.9 million [29] - Cash flow improvements were noted, with net cash used in operations declining by $2.2 million for the first six months of 2025, down to $5 million compared to $7.2 million in the same period of 2024 [29] - Cash and cash equivalents increased by 16% to $4.2 million as of June 30, 2025, up from $3.6 million at December 31, 2024 [29] - Revenue for Q2 was $1 million, with year-to-date revenue at $1.8 million [30] Business Line Data and Key Metrics Changes - BolaWrap deployments are increasing across diverse law enforcement agencies, with strong usage reported in Colorado, North Carolina, and Canada [10] - Agencies in Florida are evaluating BolaWrap as a strategic replacement for traditional electronic control devices like TASERs [10] - The crisis intervention team in a major Floridian agency reports more frequent BolaWrap use than TASERs, indicating a shift towards safer tools [11] Market Data and Key Metrics Changes - Favorable federal regulatory changes, including the Supreme Court decision in Barnes v. Felix, are driving adoption and sales of BolaWrap [15][16] - Increased inquiries and strategic discussions with customers are being observed due to heightened awareness around safer alternatives to traditional use of force tools [17] Company Strategy and Development Direction - The company has completed its restructuring efforts and is now focused on a renewed go-to-market strategy that emphasizes pre-escalation [5][40] - The introduction of new subscription models, Wrap Ready and Wrap Plus, aims to address customer concerns regarding replacement costs and enhance value propositions [31][32] - The company is expanding into adjacent markets such as healthcare, transportation, and private security, leveraging its existing technology and partnerships [26][64] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum building for Wrap Technologies, citing a sharp increase in purchase orders and positive customer feedback [4][40] - The company believes it is well-positioned to capitalize on the evolving regulatory landscape and increasing demand for safer policing tools [40] - Management highlighted the importance of training and partnerships in driving adoption and success in the market [25][52] Other Important Information - The company has applied for nearly $1 million in DOJ-funded grants to support pre-escalation tools and training [33] - A new counter UAS capability has been developed, targeting a growing market projected to reach $6.8 billion by 2030 [38] - The rebranding of the body-worn camera business line to WrapVision aims to address data sovereignty concerns and enhance product offerings [39] Q&A Session Summary Question: How do you plan to accelerate adoption among law enforcement agencies in the US and internationally? - Management noted that adoption is being driven by regulatory changes and direct engagement with departments, emphasizing the importance of training and connectivity with officers [42][45][50] Question: How do you plan to penetrate non-law enforcement sectors? - The company is already seeing interest from hospitals and correction facilities, with a focus on scaling operations and leveraging data to drive adoption [56][60][64] Question: Are there adjacent product lines or technology upgrades planned in the next eighteen months? - Management confirmed ongoing developments, including counter drone capabilities and enhancements to the body-worn camera line, indicating a strategic focus on expanding product offerings [67][70] Question: What is the status of the company's move to Virginia, and when do you expect production to ramp up? - The company has fully moved to Virginia and is prepared to scale production in response to increasing demand [76][78] Question: How do you see one-time sales versus subscription services as a portion of your revenues? - Management highlighted a strategic shift towards recurring subscription models, which are expected to provide more stable revenue streams compared to one-time sales [80][81]

Financial Data and Key Metrics Changes - Comstock reported a gross proceed of $30 million from a recent offering, with net proceeds of $27.6 million, increasing cash position to over $45 million [8][9][12] - The company eliminated approximately $8.4 million in promissory notes and $2.2 million in convertible notes, enhancing its financial stability [9][10][11] Business Line Data and Key Metrics Changes - The metal recycling business is experiencing rapid growth, with a focus on solar panel recycling, which is projected to scale significantly [7][16] - The company has developed a unique technology for recycling solar panels, achieving a zero landfill solution and high recovery rates of valuable metals [24][26][32] Market Data and Key Metrics Changes - The market for end-of-life solar panels is expected to grow exponentially, with projections of 33 million panels reaching the end of their life in four and a half years [42][43] - The demand for silver is at an all-time high, driven by industrial applications, particularly in electronics and solar panels, with prices rising significantly [37][38] Company Strategy and Development Direction - Comstock aims to establish itself as a leader in the solar panel recycling market, with plans to expand its facilities and increase production capacity [56][58] - The company is also focused on monetizing its mining assets and exploring opportunities in the oil and gas sector following the separation of Biolium [61][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to scale operations and meet growing market demand, emphasizing the importance of securing permits and equipment [56][89] - The company is optimistic about its competitive advantages, including a zero landfill solution and the capacity to handle large volumes of solar panels [95][96] Other Important Information - Comstock has secured land for additional storage capacity to accommodate the anticipated influx of solar panels [40] - The company is preparing to deconsolidate Biolium from its financials, which will provide clearer visibility into its metals and fuels businesses [72] Q&A Session Summary Question: Has the equipment for solar recycling been ordered? - Yes, the company has finalized the design and is ready to purchase the equipment, with deposits being made to ensure timely delivery [79] Question: What are the lead times for the equipment? - Lead times are estimated at four to six months, with all equipment being manufactured domestically to avoid tariffs [80][81] Question: Can the capital for a facility be phased in? - The company plans to deploy the entire system at once rather than phasing it in, as it makes more sense for operational efficiency [82] Question: Can facilities be permitted and built in parallel? - The company is exploring the possibility of permitting multiple sites simultaneously to expedite the process [88] Question: What is the potential market for solar panels? - The market is projected to grow significantly, with millions of panels reaching the end of their life in the coming years, translating to hundreds of thousands of tons of material [92] Question: Will long-term contracts be established for metal recycling? - The company believes that as its capabilities become clearer, longer-term contracts will be negotiated with customers [94][102] Question: Why are asset sales taking so long? - Delays in asset sales are attributed to power grid bottlenecks caused by increased demand from data centers and industrial developments [104][106]

Financial Data and Key Metrics Changes - Revenue increased by 150% year over year to $8.4 million, driven by significant sales and rentals of the mobile EV charging platform, eBoost [4][13] - Non-GAAP operating income from continuing operations was $218,000, compared to a non-GAAP operating loss of $137,000 in the same quarter last year, marking a year-over-year improvement of $355,000 [14] - Net loss from continuing operations improved to $1.2 million from $1.7 million in the previous year [14] - Cash on hand decreased to $18 million from $41.6 million at the end of 2024, primarily due to a special cash dividend and tax payments [15] Business Line Data and Key Metrics Changes - The eBoost order for a large public school district significantly contributed to revenue growth, with gross profit on these units more than doubling in the second quarter [5][13] - The company delivered initial units under the SparkCharge agreement, which could be worth up to $10 million, reflecting increasing demand for mobile EV charging solutions [5] Market Data and Key Metrics Changes - Total backlog was approximately $18 million, a decline of 23% compared to the prior quarter due to fulfillment of larger orders [6][7] - The electric school bus market continues to show strong momentum, with the school district scheduled to receive an additional 600 electric school buses over the next two years [5] Company Strategy and Development Direction - The company is focused on scaling its core business and launching HomeBoost, a residential and light commercial power system, expected to expand its addressable market [8][9] - The company sees growth potential in autonomous mobility, particularly in the robotaxi segment, which aligns with its mobile charging platform [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the business and the demand environment, with a reaffirmation of revenue guidance for the full year of $27 million to $29 million [16][10] - The company is optimistic about the breadth and quality of future opportunities, particularly in government agencies and transit authorities [5][10] Other Important Information - The company is preparing to launch HomeBoost, which integrates a natural gas engine with optional DC fast charging, expected to be a key growth driver for 2026 and beyond [9] - Management emphasized the importance of operational efficiency and productivity gains in achieving profitability [10] Q&A Session Summary Question: Details on the eBoost order with the charging services company - Management explained that the order could be up to $10 million, with variables based on size and timing of delivery [22] Question: Insights on the sales pipeline and order visibility - Management noted that government agencies move at different paces, while private businesses tend to be quicker in decision-making [26] Question: Launch milestones for HomeBoost - The launch has been delayed due to internal adjustments, with expectations for orders to begin in 2025 and accelerate in 2026 [30] Question: Future margin expectations - Management indicated that margins should remain stable or improve, with no expected erosion [34] Question: Revenue concentration and market evolution - California remains the primary market, but success with HomeBoost could diversify revenue sources [40] Question: Competitive landscape for eBoost and HomeBoost - Management noted reduced competition in the eBoost space, while HomeBoost is being kept under wraps until fully ready for market [60][61]

Talphera (TLPH) Q2 2025 Earnings Call August 14, 2025 04:30 PM ET Speaker0Welcome to the Telfaira Second Quarter twenty twenty five Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Telfaira's website at www.talfera.com. You may listen to a replay of this webcast by going to the Investors section of Telfaira's website. I would now like to turn the call over to Raffi Azadorian, Talfera's Chief Financial Officer.Speaker1Thanks, Andrew, and thank ...

Financial Data and Key Metrics Changes - In Q2 2025, total recognized revenue was approximately $1,000,000, a decline of 66% from $3,000,000 in Q2 2024, primarily due to customers deferring capital expenditure projects [14] - Service revenue for the quarter was $378,000, representing a 33% increase year-over-year, while service revenue for the first six months reached $955,000, a 299% increase [15] - Gross margin improved to 66% in Q2 2025, up from 62% in the same quarter last year, attributed to a favorable product mix [15] Business Line Data and Key Metrics Changes - Service revenue from IHP service deployments and validation support services grew by 33% compared to the same period last year and by 46% over the first six months [8] - BIT solution sales saw a 40% increase year-to-date, with expectations for continued growth due to repeat orders [10] - The company has a sales order backlog of approximately $4,600,000, with active projects scheduled for delivery in 2025 [7] Market Data and Key Metrics Changes - The company is negotiating approximately $2,000,000 in new custom and integrated contracts, with bids expected to close before year-end [7] - Open opportunities for three product offerings total approximately $15,000,000, with $7,000,000 designated as high priority [7] - The USDA increased its usage of SteraMist in Q2 2025, indicating growing market acceptance [12] Company Strategy and Development Direction - The company is focused on expanding customer outreach through targeted marketing strategies and strategic partnerships [9] - There is an emphasis on educating the market about proactive disinfection through the SteriMist Pro certified program [10] - The company aims to enhance its infrastructure by strengthening personnel in management and expanding its global distributor network [28] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about maintaining a positive trajectory for the remainder of 2025, despite challenges faced in Q2 [6] - The company anticipates significant orders from large companies as new manufacturing plants are built in the U.S. [38] - Management is hopeful that upcoming regulatory approvals will significantly impact growth [29] Other Important Information - The company was recognized as the Disinfection, Decontamination, and Disinfection Product Company of the Year for 2025 [12] - The company is developing a scalable solution to replace outdated methods in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases [21] - There is a strong pipeline of international partnerships in Europe, with pending approvals expected soon [23] Q&A Session Summary Question: Can you provide margins realized in solution sales compared to the rest of the business? - Management expressed excitement about solution sales, noting high margins and an increase in gross margins to 66% this quarter [33] Question: What opportunities arise from the strategy to bring back pharma manufacturing to the U.S.? - Management highlighted that high regulatory standards present opportunities for significant orders from large companies as new facilities are built [38] Question: Have any customers that deferred CapEx projects notified you about moving ahead? - Management indicated a significant increase in customer deposits and confirmed that at least two customers are expected to proceed with projects in 2026 [41] Question: Can you describe how SteraMist would be used if FDA approvals are obtained? - Management detailed ongoing FDA approval processes for medical devices and food safety applications, emphasizing the potential for expanded market opportunities [43][44] Question: Any new uses developed for SteraMist? - Management mentioned ongoing internal tests for new applications, including extending the shelf life of flowers, but noted hurdles to overcome before entering new industries [46]

Financial Data and Key Metrics Changes - Net sales grew 23% year over year to $16.2 million, marking the third consecutive quarter of revenue growth [5][19] - Gross profit increased 45.4% to $4.6 million, with gross margin expanding 430 basis points to 28.3% [19] - Operating expenses decreased to $7.9 million from $9.9 million, reflecting lower R&D costs [19] - Net loss improved to $7 million or $0.58 per share, compared to a net loss of $13.6 million or $2.02 per share [19] - Adjusted EBITDA improved to negative $2.2 million from negative $6.2 million [19] Business Line Data and Key Metrics Changes - OEM segment net sales rose over 50% year over year to $10.1 million, driven by strong adoption of solutions [5][19] - DTC segment net sales were $5.9 million, down from $6.5 million due to macroeconomic uncertainties [6][19] Market Data and Key Metrics Changes - The company noted a shift in the industry towards premium features and value-added offerings, contrasting with previous cost-reduction strategies [6] - The heavy-duty trucking market remains challenging, but pilot programs are showing positive results [16] Company Strategy and Development Direction - The company is focused on expanding OEM partnerships and leveraging engineering capabilities to deliver integrated solutions [6][11] - Domestic manufacturing capabilities are emphasized as a strategic advantage in a volatile trade environment [8][9] - The company is committed to innovation, recently granted a patent for a non-flammable all-solid-state battery program [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to capitalize on growth opportunities despite a challenging macro environment [11][21] - The company anticipates net sales of $15.9 million in Q3, representing approximately 25% year-over-year growth [21] - Management is optimistic about the ramp-up of pilot programs in the heavy-duty trucking sector [30] Other Important Information - The company completed a public offering raising $5.5 million to support expansion into adjacent markets [10] - The company has optimized its capital structure by exchanging preferred shares for common stock, eliminating associated interest payments [10] Q&A Session Summary Question: When do you expect pilot programs in heavy-duty trucking to impact P&L? - Management expects revenue impact in the first half of next year as fleets await new truck orders [25] Question: How should tariffs impact P&L in the coming quarters? - Management has managed tariff impacts through better inventory pricing and onshoring components, maintaining confidence in managing costs [27][28] Question: Should we expect sequential improvement in Q4? - Management anticipates sequential improvement driven by RV industry growth and new market contributions [31] Question: Can you discuss the recent patent awarded? - The patent relates to the preparation of feedstock for solid-state batteries, crucial for the dry electrode process [34]